Protocol Ledger

NCT05976763 · Phase III · RECRUITING

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Interventional Phase III clinical trial protocol NCT05976763 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-20 Enrollment: 421 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05976763
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)421 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05976763
Protocol FieldVerified Registry Value
NCT IdentifierNCT05976763
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment421 participants (ESTIMATED)
Registered Start Date2023-10-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI